Previous close | 1.6900 |
Open | 1.7500 |
Bid | 1.7400 x 6000 |
Ask | 1.7700 x 4400 |
Day's range | 1.6900 - 1.8700 |
52-week range | 1.2500 - 14.5500 |
Volume | |
Avg. volume | 10,046,752 |
Market cap | 479.324M |
Beta (5Y monthly) | 1.83 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's National Biobank, has chosen the Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its populational health data. The announcement follows funding from the European Commission and the Estonian government to help Estonia adopt personalized medicine at scale and adapt public health systems to
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan